77 related articles for article (PubMed ID: 23955079)
1. Opportunities and hurdles in the treatment of BRCA1-related breast cancer.
Drost R; Jonkers J
Oncogene; 2014 Jul; 33(29):3753-63. PubMed ID: 23955079
[TBL] [Abstract][Full Text] [Related]
2. Hereditary breast cancer syndromes and genetic testing.
Rich TA; Woodson AH; Litton J; Arun B
J Surg Oncol; 2015 Jan; 111(1):66-80. PubMed ID: 25381882
[TBL] [Abstract][Full Text] [Related]
3. An update on PARP inhibitors--moving to the adjuvant setting.
Sonnenblick A; de Azambuja E; Azim HA; Piccart M
Nat Rev Clin Oncol; 2015 Jan; 12(1):27-41. PubMed ID: 25286972
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 is a histone-H2A-specific ubiquitin ligase.
Kalb R; Mallery DL; Larkin C; Huang JT; Hiom K
Cell Rep; 2014 Aug; 8(4):999-1005. PubMed ID: 25131202
[TBL] [Abstract][Full Text] [Related]
5. 53BP1, BRCA1, and the choice between recombination and end joining at DNA double-strand breaks.
Daley JM; Sung P
Mol Cell Biol; 2014 Apr; 34(8):1380-8. PubMed ID: 24469398
[TBL] [Abstract][Full Text] [Related]
6. BRCA1 as target for breast cancer prevention and therapy.
Romagnolo AP; Romagnolo DF; Selmin OI
Anticancer Agents Med Chem; 2015; 15(1):4-14. PubMed ID: 25329591
[TBL] [Abstract][Full Text] [Related]
7. BMI-1 promotes breast cancer proliferation and metastasis through different mechanisms in different subtypes.
Liu JY; Jiang YN; Huang H; Xu JF; Wu YH; Wang Q; Zhu Y; Zheng B; Shen C; Qian WF; Shen J
Cancer Sci; 2023 Feb; 114(2):449-462. PubMed ID: 36285479
[TBL] [Abstract][Full Text] [Related]
8. Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target.
Raimundo L; Calheiros J; Saraiva L
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298653
[TBL] [Abstract][Full Text] [Related]
9. BBIT20 inhibits homologous DNA repair with disruption of the BRCA1-BARD1 interaction in breast and ovarian cancer.
Raimundo L; Paterna A; Calheiros J; Ribeiro J; Cardoso DSP; Piga I; Neto SJ; Hegan D; Glazer PM; Indraccolo S; Mulhovo S; Costa JL; Ferreira MU; Saraiva L
Br J Pharmacol; 2021 Sep; 178(18):3627-3647. PubMed ID: 33899955
[TBL] [Abstract][Full Text] [Related]
10. PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors.
Bai F; Liu S; Liu X; Hollern DP; Scott A; Wang C; Zhang L; Fan C; Fu L; Perou CM; Zhu WG; Pei XH
Breast Cancer Res; 2021 Jan; 23(1):10. PubMed ID: 33478572
[TBL] [Abstract][Full Text] [Related]
11. A Novel Mutation-BRCA1 Associated Hereditary Haplotype of Intragenic Markers of BRCA1 Gene in a Family with History of Breast Cancer.
Miresmaeili SM; Jafari F
Asian Pac J Cancer Prev; 2019 Feb; 20(2):611-614. PubMed ID: 30806067
[TBL] [Abstract][Full Text] [Related]
12. Expression of miR-146a-5p in breast cancer and its role in proliferation of breast cancer cells.
Gao W; Hua J; Jia Z; Ding J; Han Z; Dong Y; Lin Q; Yao Y
Oncol Lett; 2018 Jun; 15(6):9884-9888. PubMed ID: 29928360
[TBL] [Abstract][Full Text] [Related]
13. PARP Inhibition by Flavonoids Induced Selective Cell Killing to BRCA2-Deficient Cells.
Su C; Haskins AH; Omata C; Aizawa Y; Kato TA
Pharmaceuticals (Basel); 2017 Oct; 10(4):. PubMed ID: 29023372
[TBL] [Abstract][Full Text] [Related]
14. Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms.
Wu H; Wu X; Liang Z
Gene Ther; 2017 Oct; 24(10):601-609. PubMed ID: 28771233
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 Mutation Leads to Deregulated Ubc9 Levels which Triggers Proliferation and Migration of Patient-Derived High Grade Serous Ovarian Cancer and Triple Negative Breast Cancer Cells.
Xu J; Footman A; Qin Y; Aysola K; Black S; Reddy V; Singh K; Grizzle W; You S; Moellering D; Reddy ES; Fu Y; Rao VN
Int J Chronic Dis Ther; 2016; 2(3):31-38. PubMed ID: 28164176
[TBL] [Abstract][Full Text] [Related]
16. Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor olaparib by a dominant negative effect.
Vaclová T; Woods NT; Megías D; Gomez-Lopez S; Setién F; García Bueno JM; Macías JA; Barroso A; Urioste M; Esteller M; Monteiro ANA; Benítez J; Osorio A
Hum Mol Genet; 2016 Dec; 25(24):5287-5299. PubMed ID: 27742776
[TBL] [Abstract][Full Text] [Related]
17. Emerging therapeutic targets in metastatic progression: A focus on breast cancer.
Li Z; Kang Y
Pharmacol Ther; 2016 May; 161():79-96. PubMed ID: 27000769
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.
Matamala N; Vargas MT; González-Cámpora R; Arias JI; Menéndez P; Andrés-León E; Yanowsky K; Llaneza-Folgueras A; Miñambres R; Martínez-Delgado B; Benítez J
Oncotarget; 2016 Apr; 7(15):20068-79. PubMed ID: 26933805
[TBL] [Abstract][Full Text] [Related]
19. Cooperation between BRCA1 and vitamin D is critical for histone acetylation of the p21waf1 promoter and growth inhibition of breast cancer cells and cancer stem-like cells.
Pickholtz I; Saadyan S; Keshet GI; Wang VS; Cohen R; Bouwman P; Jonkers J; Byers SW; Papa MZ; Yarden RI
Oncotarget; 2014 Dec; 5(23):11827-46. PubMed ID: 25460500
[TBL] [Abstract][Full Text] [Related]
20. A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy.
Liu C; Srihari S; Cao KA; Chenevix-Trench G; Simpson PT; Ragan MA; Khanna KK
Nucleic Acids Res; 2014 Jun; 42(10):6106-27. PubMed ID: 24792170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
